Skip to main content
. 2011 Nov;179(5):2327–2336. doi: 10.1016/j.ajpath.2011.08.001

Figure 3.

Figure 3

Effects of recombinant IL-27 (rIL-27) on hyperglycemia and β-cell injury induced by STZ. A: Gene expression of WSX-1, gp130, and β-actin in thymus and pancreatic islets. Total RNA extracted from thymus and pancreatic islets of WT mice was examined by RT-PCR in the absence or presence of reverse transcriptase (RT). A representative gel image is shown. B: Effects of rIL-27 on STZ-induced hyperglycemia. Nonfasting blood glucose levels were measured in WT mice (black bar), EBI3−/− mice (white bar), and WSX-1−/− mice (gray bar) treated with STZ in combination with rIL-27 or control vehicle, before (day 0) and on days 7 and 14 after STZ treatment (n = 10 to 12 per group). Data shown are the mean ± SE. *P < 0.05 versus WT mice treated with STZ alone on day 0; **P < 0.05 versus EBI3−/− mice treated with STZ alone on day 0; ***P < 0.05 versus WT mice treated with STZ alone on day 14; †P < 0.05 versus EBI3−/− mice treated with STZ alone on day 7; ††P < 0.05 versus EBI3−/− mice treated with STZ alone on day 14. C: Representative photomicrographs of H&E-stained islets from WT, EBI3−/−, and WSX-1−/− mice treated with STZ in combination with rIL-27 or control vehicle. Scale bar = 20 μm. D: Representative photomicrographs of islets from WT, EBI3−/−, and WSX-1−/− mice treated with STZ in combination with rIL-27 or control vehicle stained with anti-insulin C-chain antibody and examined by immunofluorescence (left panel). Scale bar = 20 μm. Fluorescence intensity was expressed as relative to that of WT mice treated with control vehicle (right panel). *P < 0.05 versus STZ treatment alone in WT mice; **P < 0.05 versus STZ treatment alone in EBI3−/− mice.